Ghost Tree Capital’s Protagonist Therapeutics PTGX Stock Holding History

Ghost Tree Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-75,000	Closed	-$2.17M	–	79
2024 Q1	$2.17M	Sell	75,000 -50,000	-40%	-$1.36M	0.6%	55
2023 Q4	$2.87M	Sell	125,000 -275,000	-69%	-$4.81M	0.94%	34
2023 Q3	$6.67M	Buy	400,000 +175,000	+78%	+$3.4M	2.19%	15
2023 Q2	$6.21M	Hold	225,000	–	–	2.05%	19
2023 Q1	$5.17M	Buy	+225,000	New	+$3.78M	1.53%	28
2020 Q2	–	Sell	-227,827	Closed	-$1.61M	–	49
2020 Q1	$1.61M	Sell	227,827 -47,173	-17%	-$353K	0.43%	41
2019 Q4	$1.94M	Buy	275,000 +25,000	+10%	+$248K	0.37%	47
2019 Q3	$3M	Buy	250,000 +50,000	+25%	+$630K	0.77%	36
2019 Q2	$2.42M	Sell	200,000 -500,000	-71%	-$5.53M	0.5%	39
2019 Q1	$8.8M	Buy	+700,000	New	+$6.18M	2.3%	18

Other funds holding PTGX

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ghost Tree Capital's PTGX Position: Q2 2024 in Review

Ghost Tree Capital sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 75,000 shares — an estimated $2.17M sold.

Ghost Tree Capital first reported a position in PTGX in Q1 2019 and held it in 10 quarters. The position peaked at $8.8M in Q1 2019. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

Ghost Tree Capital reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
Ghost Tree Capital sold 75,000 Protagonist Therapeutics shares in Q2 2024, an estimated $2.17M.
Ghost Tree Capital first reported a position in Protagonist Therapeutics in Q1 2019 and held it in 10 quarters.
Ghost Tree Capital's Protagonist Therapeutics position peaked at $8.8M in Q1 2019.
188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.